查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931177

生命科學領域人工智慧市場：按組件、資料類型、部署方式、技術、最終用戶和應用分類的全球預測（2026-2032年）

Artificial Intelligence in Life Sciences Market by Component, Data Type, Deployment, Technology, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生命科學領域的人工智慧 (AI) 市場價值將達到 110.9 億美元，到 2026 年將成長至 129.4 億美元，複合年成長率為 17.95%，到 2032 年將達到 352.5 億美元。

關鍵市場統計數據
基準年 2025 110.9億美元
預計年份：2026年 129.4億美元
預測年份 2032 352.5億美元
複合年成長率 (%) 17.95%

透過概述機會、科學促進因素和決策者可採取的實際路徑，為生命科學領域的人工智慧設定策略背景。

人工智慧不再只是生命科學領域的實驗輔助手段，它已成為推動藥物發現、開發、臨床營運和患者照護等各個環節策略發展的驅動力。現代人工智慧方法融合了演算法進步、可擴展計算以及更豐富、更多樣化的生物醫學資料集，能夠比傳統工作流程更快地產生假設、最佳化標靶選擇並提取具有臨床意義的洞見。因此，領導者必須重新定義人工智慧，將其從技術投資轉變為一項跨職能的變革，整合科學、監管和營運等各個領域。

整體情況正在重新定義生命科學組織如何發展治療方法、管理數據和提供護理的變革性技術、監管和組織變革。

生命科學領域的人工智慧正從孤立的先導計畫轉向廣泛的生態系統層面變革，這將重塑科學研究和醫療服務的提供方式。專用處理器、可擴展的雲端基礎設施和模組化軟體堆疊的技術進步，使得建立大規模的模型和複雜的多模態分析流程成為可能。同時，自然語言處理和電腦視覺技術的進步，也為解讀臨床記錄、病理切片和放射學研究開闢了新的途徑，創造了以往難以實現的工作流程。

分析2025年美國關稅對生命科學人工智慧供應鏈、運算資源採購和全球合作動態的累積影響

美國宣布將於2025年調整關稅政策，將為全球生命科學供應鏈引入新的變數，並對人工智慧的應用產生累積效應。最直接的影響將體現在硬體採購方面，尤其是用於模型訓練和推理的高效能處理器和加速器。關稅上調將增加實際採購成本，並使供應商選擇更加複雜，促使買家重新評估其整體擁有成本（TCO）和供應商多元化策略。

解讀部署模型、元件、資料類型、最終使用者、技術和應用領域等方面的細微細分趨勢，以指導產品和銷售策略。

對市場區隔進行層級分解，可以揭示價值集中和營運風險集中的區域，從而為產品開發和商業策略提供明確的優先順序。在考慮部署方案時，涵蓋混合雲端、私有雲端和公共雲端的雲端環境能夠提供所需的彈性和託管服務，加速模型實驗。同時，當資料居住、延遲或特定監管限制需要本地管理時，本地資料中心部署仍然至關重要。決策框架應考慮能夠平衡洞察速度和管治要求的混合架構。

區域情報整合了美洲、歐洲、中東和非洲以及亞太市場的創新生態系統、監管差異和採用速度。

區域趨勢塑造著創新熱點、不斷演變的法規結構以及商業性應用的步伐。美洲地區環境多元化，領先的研究機構、大規模醫療系統和強大的創投生態系統推動快速的實驗性創新。該地區的政策和報銷趨勢能夠加速那些展現出臨床效用和成本效益的解決方案的商業化進程，而各州和各系統之間的碎片化則使得互通性和靈活的應用模式顯得尤為重要。

分析塑造人工智慧賦能的生命科學工作流程和夥伴關係的主要企業、新興企業和平台供應商的策略行動和產品定位

引領人工智慧生命科學領域的公司正在採取獨特的策略姿態，這反映了競爭與合作的演變。平台提供者和超大規模資料中心業者供應商強調整合式解決方案，透過提供託管運算、資料湖和模型運行工具來加速價值實現；而專業供應商則專注於垂直整合的解決方案，例如針對基因組學或放射學等特定領域的解決方案。Start-Ups通常專注於小眾但影響巨大的應用場景，以快速檢驗臨床效用並與大型企業建立合作關係。

為經營團隊提供實用建議，幫助他們優先考慮投資、管治、技能和夥伴關係，以加速在生命科學領域安全、合規且商業性成功的AI應用。

領導者應優先考慮能夠將技術潛力轉化為持續的臨床和商業性價值的投資和管治結構。首先，組織應採用以用主導的投資方法，將資源集中於具有高影響力的臨床問題和可衡量的終點指標，而非探索性的功能集。這種方法可以減少浪費，並加快相關人員的接受度。其次，強制執行可重複性、可解釋性和生命週期監管的管治框架可以降低監管和營運風險，並增強臨床醫生和患者之間的信任。

透明的調查方法，詳細說明了用於建構人工智慧生命科學現狀可靠圖景的資料來源、分析框架、檢驗方法和品管。

該研究整合了來自行業領袖訪談、技術檢驗練習以及同行評審期刊、監管指南和已發布產品應用等二手文獻的定性和定量證據。透過對資訊來源進行三角驗證，確保結論反映了來自實踐經驗、技術基準和監管趨勢的趨同證據。分析框架結合了技術堆疊觀點、資料生命週期分析和市場推廣路徑規劃，從部署模式、元件、資料類型、最終使用者、技術和應用領域等多個維度評估機會和風險。

這是一份綜合性報告，提煉出醫療保健系統領導者、生物製藥經營團隊和研究機構需要關注的策略要務、風險緩解策略和後續步驟。

對現有證據的綜合分析凸顯了幾個關鍵的持續挑戰：將人工智慧投資與明確的臨床和研究成果相匹配；加強對管治和可重複性的投入以滿足監管要求；以及採用靈活的架構，在創新速度、數據主權和運營穩定性之間取得平衡。遵循這些原則的機構將更有能力將技術進步轉化為研發流程、臨床工作流程和病患療效的可衡量改進。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 生命科學領域人工智慧市場（按組件分類）

  • 硬體
    • 處理器和加速器
    • 伺服器和工作站
    • 儲存網路
  • 服務
    • 諮詢
    • 一體化
    • 支援與維護
  • 軟體
    • 平台
    • 解決方案
    • 工具和框架

9. 生命科學領域人工智慧市場（按資料類型分類）

  • 臨床數據
    • 電子健康記錄
    • 測試結果
  • 基因組數據
    • 基因表現數據
    • 定序數據
  • 影像資料
    • 電腦斷層掃描
    • MRI
    • 超音波
    • X光

第10章 生命科學領域人工智慧市場（以部署方式分類）

  • 雲
    • 混合雲端
    • 私有雲端
    • 公共雲端
  • 本地部署

第11章 生命科學領域的人工智慧市場（按技術分類）

  • 電腦視覺
    • 3D重建
    • 醫學影像分析
    • 模式識別
  • 機器學習
    • 深度學習
    • 強化學習
    • 監督式學習
    • 無監督學習
  • 自然語言處理
    • 語意分析
    • 語音辨識
    • 文字探勘
  • 預測分析
    • 預測結果
    • 風險建模
  • 機器人流程自動化

第12章 生命科學領域人工智慧市場（按最終用戶分類）

  • 合約研究機構
  • 醫療保健提供者
    • 診所
    • 診斷中心
    • 醫院
  • 製藥和生物技術公司
  • 研究所

第13章 生命科學領域人工智慧市場（按應用分類）

  • 臨床試驗管理
    • 資料管理
    • 病患招募
    • 測試設計
  • 診斷和影像診斷
    • 基因組成像
    • 病理影像診斷
    • 放射影像診斷
  • 藥物發現
    • 先導藥物最適化
    • 目標識別
    • 毒性預測
  • 病患監測
    • 遠端監控
    • 穿戴式裝置
  • 個人化治療
    • 劑量最佳化
    • 精準醫療

第14章 生命科學領域人工智慧市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 生命科學領域人工智慧市場（按地區分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國生命科學人工智慧市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國生命科學領域的人工智慧市場

第18章：中國生命科學領域的人工智慧市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Atomwise
  • BenevolentAI
  • BioAge Labs
  • Cyclica
  • Exscientia
  • GNS Healthcare
  • Google Health
  • Healx
  • IBM Watson Health
  • Iktos
  • Insilico Medicine
  • Microsoft Corporation
  • NVIDIA Corporation
  • PathAI
  • Recursion Pharmaceuticals
  • ReviveMed
  • Schrodinger, Inc.
  • SOPHiA GENETICS
  • Standigm
  • Tempus Labs
  • Valo Health
  • Verily Life Sciences
  • XtalPi
  • Zephyr AI
Product Code: MRR-7B550E008D9D

The Artificial Intelligence in Life Sciences Market was valued at USD 11.09 billion in 2025 and is projected to grow to USD 12.94 billion in 2026, with a CAGR of 17.95%, reaching USD 35.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.09 billion
Estimated Year [2026] USD 12.94 billion
Forecast Year [2032] USD 35.25 billion
CAGR (%) 17.95%

Setting the strategic context for artificial intelligence in life sciences by framing opportunities, scientific drivers, and practical adoption pathways for decision-makers

Artificial intelligence is no longer an experimental adjunct in life sciences; it has become a strategic enabler that touches discovery, development, clinical operations, and patient care. Contemporary AI approaches combine advances in algorithms, scalable compute, and richer, more diverse biomedical datasets to create capabilities that accelerate hypothesis generation, refine target selection, and surface clinically actionable insights with greater speed than traditional workflows. As a result, leaders must reframe AI from a narrow technological investment to a cross-functional transformation that integrates scientific, regulatory, and operational domains.

Adoption pathways vary widely across organizations, but common drivers include the need to reduce time to insight, improve reproducibility, and manage exponentially growing volumes of genomic, imaging, and clinical data. Equally important are regulatory expectations for explainability and data provenance, plus the operational demands of deploying models where clinical and lab workflows intersect. Taken together, these forces require an approach that balances agility in innovation with disciplined governance, scalable infrastructure, and close collaboration among data scientists, clinicians, and compliance teams.

In the coming years, leaders who align technology choices with real clinical and research use cases will capture disproportionate value. This begins with a clear problem definition, iterative validation against high-quality data, and an organizational commitment to reskilling and cross-functional collaboration. By anchoring AI programs to measurable outcomes and robust risk management, institutions can realize practical benefits while maintaining patient safety and regulatory compliance.

Mapping transformative technological, regulatory, and organizational shifts that are redefining how life sciences organizations develop therapies, manage data, and deliver care

The landscape for AI in life sciences has shifted from isolated pilot projects to broad ecosystem-level changes that reshape how research and care are delivered. Technological progress in specialized processors, scalable cloud infrastructures, and modular software stacks is enabling much larger models and more complex multi-modal analytic pipelines. At the same time, advances in natural language processing and computer vision are unlocking new ways to interpret clinical notes, pathology slides, and radiology studies, thereby creating workflows that were previously impractical.

Regulatory frameworks and payer expectations are also evolving, prompting organizations to strengthen model validation, documentation, and post-deployment monitoring. This regulatory tightening acts as both a constraint and an opportunity: those that invest early in explainability, reproducibility, and lifecycle management gain a competitive advantage by reducing downstream friction and accelerating approval trajectories. Furthermore, the maturation of data stewardship practices and federated analytics approaches is changing competitive dynamics by enabling collaborative discovery without surrendering data control.

Organizationally, the shift toward productized AI requires new operating models that blend clinical domain knowledge with software engineering and data operations. Cross-functional platforms that standardize data ingestion, model development, and deployment pipelines reduce redundancy and accelerate value capture. As a result, companies are moving away from one-off solutions toward platform strategies that scale across therapeutic areas, clinical functions, and geographic markets.

Analyzing the cumulative effects of United States tariff measures announced for 2025 on AI supply chains, compute sourcing, and global collaboration dynamics in life sciences

Tariff policy changes announced for 2025 in the United States introduce a new variable into global life sciences supply chains that will have cumulative effects on AI deployments. The most immediate impact is on hardware sourcing, particularly high-performance processors and accelerators used for model training and inference. Increased tariffs raise the effective procurement cost and complicate vendor selection, encouraging buyers to reassess total cost of ownership and supplier diversification strategies.

Beyond hardware, tariffs influence the flow of preconfigured systems, storage arrays, and integrated platforms that are often supplied by global vendors. Organizations will likely respond by increasing use of local assembly, negotiating pricing adjustments, or shifting more workloads toward software-centric solutions that leverage cloud providers with localized data centers. These adjustments have implications for reproducibility and validation, because development environments may fragment across regions, requiring stronger configuration management and validation protocols to ensure consistent model behavior.

Tariff-driven changes also alter collaboration dynamics. Cross-border partnerships in areas such as multi-site clinical trials, federated learning initiatives, and contract research engagements may face additional administrative and logistical hurdles. As a result, stakeholders should expect longer procurement cycles, a renewed emphasis on supplier risk assessments, and potentially higher investments in interoperability and containerized deployment models that reduce dependence on specific hardware footprints. In sum, tariff policy becomes a strategic factor in architecture decisions, partner selection, and the economics of scaling AI in life sciences.

Interpreting nuanced segmentation dynamics across deployment models, components, data types, end users, technologies, and application areas to guide product and sales strategies

Decomposing the market through layered segmentation reveals where value and operational risk concentrate, and it suggests clear priorities for product development and commercial strategies. When considering deployment options, cloud environments-spanning hybrid cloud, private cloud, and public cloud-offer elasticity and managed services that accelerate model experimentation, while on-premise local data center deployments remain essential where data residency, latency, or specific regulatory constraints demand localized control. Decision frameworks should account for hybrid architectures that balance speed to insight with governance needs.

From a component perspective, hardware investments in processors and accelerators, servers and workstations, and storage and networking underpin performance, but they must be complemented by services such as consulting, integration, and support and maintenance to operationalize solutions effectively. Software layers that include platforms, solutions, and tools and frameworks are the connective tissue that turns compute into usable workflows; product teams must prioritize interoperability, extensibility, and modularity to reduce integration friction.

Data type segmentation underscores that clinical, genomic, and imaging datasets each present distinct technical and compliance challenges. Clinical datasets, including electronic health records and lab results, require robust de-identification and harmonization pipelines. Genomic data such as gene expression and sequencing outputs demand specialized storage, compute, and lineage tracking. Imaging modalities ranging from CT and MRI to ultrasound and X-ray necessitate high-throughput image processing and standardized annotation schemas to facilitate model training and cross-site validation.

End-user segmentation clarifies commercial routes to market and implementation pathways. Contract research organizations, split between clinical and preclinical CROs, pursue automation and predictive analytics to accelerate study timelines. Healthcare providers across clinics, diagnostic centers, and hospitals prioritize integration with clinical workflows and measurable impact on patient outcomes. Pharmaceutical and biotechnology companies, from biotech SMEs to large pharma, focus on drug discovery and translational pipelines. Research organizations, including academic laboratories and government institutes, often lead methodological innovation and data sharing initiatives.

Technology and application segmentation identifies where technical differentiation emerges. Computer vision capabilities such as 3D reconstruction, medical imaging analysis, and pattern recognition have immediate impact in diagnostics and imaging. Machine learning approaches spanning deep learning, reinforcement learning, supervised and unsupervised learning enable predictive modeling and adaptive trial designs. Natural language processing techniques including semantic analysis, speech recognition, and text mining unlock insights from clinical narratives. Predictive analytics applied to outcome prediction and risk modeling inform patient stratification and resource allocation. These technology building blocks map directly to applications like clinical trial management, where data management, patient recruitment, and trial design benefit from automation; diagnostics and imaging across genomic, pathology, and radiology domains; drug discovery functions such as lead optimization, target identification, and toxicology prediction; patient monitoring through remote devices; and treatment personalization, including dose optimization and precision medicine.

Regional intelligence synthesizing innovation ecosystems, regulatory divergence, and adoption velocities across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics shape where innovation concentrates, how regulatory frameworks evolve, and the pace of commercial adoption. The Americas represent a heterogeneous environment where leading research institutions, sizable healthcare systems, and a strong venture ecosystem drive rapid experimentation. Policy and reimbursement trends in this region can accelerate commercialization for solutions that demonstrate clinical utility and cost effectiveness, while fragmentation across states and systems places a premium on interoperability and adaptable deployment models.

Europe, Middle East & Africa presents diverse regulatory regimes and healthcare structures, which create both barriers and opportunities. In parts of this region, strong data protection norms and centralized health systems facilitate large, standardized datasets that can support robust model validation, whereas market fragmentation and variable digital maturity require flexible commercialization approaches. Collaborative initiatives across national boundaries and public-private partnerships often play a critical role in scaling pilots to national programs.

Asia-Pacific combines fast adoption of digital health technologies with strong manufacturing ecosystems for hardware and components. Several countries in this region have prioritized national AI and genomics strategies, which bolster investments in research infrastructure and public health analytics. The region also offers significant talent pools in software engineering and data sciences, enabling rapid development of localized solutions. However, regulatory heterogeneity and localization requirements mean that global vendors must adapt offerings to meet specific compliance and market access needs. Across regions, successful strategies reconcile global platform efficiencies with local implementation and regulatory nuances.

Profiling strategic behaviors and product positioning of leading companies, emergent challengers, and platform providers shaping AI-enabled life sciences workflows and partnerships

Companies shaping the AI life sciences landscape adopt distinct strategic postures that reveal how competition and collaboration will evolve. Platform providers and hyperscalers emphasize integrated stacks that reduce time to value by offering managed compute, data lakes, and model operationalization tools, while specialized vendors focus on verticalized solutions tuned to particular modalities such as genomics or radiology. Startups typically concentrate on narrow, high-impact use cases to validate clinical utility quickly and attract partnerships with larger incumbents.

Strategic alliances and commercial partnerships dominate go-to-market approaches, with technology vendors teaming with contract research organizations, health systems, and biopharma companies to co-develop and scale solutions. These partnerships often combine domain expertise, clinical access, and data resources from life sciences organizations with engineering, deployment, and support capabilities from technology firms. Consequently, licensing models, outcome-based contracts, and managed service offerings have emerged as important commercial constructs.

Open science and consortium models remain influential among research organizations and academic laboratories, facilitating method sharing and federated experiments that accelerate collective learning. Meanwhile, firms that invest in reproducibility, regulatory documentation, and post-market surveillance position themselves to capture more conservative buyers such as large pharmaceutical companies and health systems. Ultimately, the competitive landscape rewards companies that align technological capabilities with validated clinical outcomes and robust compliance frameworks.

Actionable executive recommendations that prioritize investment, governance, skills, and partnerships to accelerate safe, compliant, and commercially successful AI adoption in life sciences

Leaders must prioritize investments and governance mechanisms that convert technological potential into sustained clinical and commercial value. First, organizations should adopt a use-case driven investment approach that focuses resources on high-impact clinical problems and measurable endpoints rather than exploratory feature sets. This orientation reduces waste and accelerates stakeholder buy-in. Second, governance frameworks that mandate reproducibility, explainability, and lifecycle monitoring will reduce regulatory and operational risk and increase trust among clinicians and patients.

Third, talent strategies should combine targeted hiring with comprehensive reskilling programs so that clinicians, data scientists, and engineers can collaborate effectively. Cross-functional teams that balance domain expertise with software and data operations skill sets are essential for operationalizing models at scale. Fourth, architecture decisions must be pragmatic: hybrid deployments can leverage cloud agility while preserving local control for sensitive data, and modular software designs reduce integration overhead and enable rapid iteration.

Fifth, procurement and partner strategies should explicitly account for supply chain risk and tariff exposure by diversifying suppliers, favoring vendor neutrality in hardware dependencies, and negotiating service level agreements that include compliance and maintenance commitments. Finally, organizations should build measurement systems that tie AI initiatives to downstream clinical and financial outcomes, enabling continuous learning and clear ROI assessments that support sustained investment.

Transparent research methodology detailing data sources, analytic frameworks, validation approaches, and quality controls used to construct a reliable picture of the AI life sciences landscape

This research synthesizes qualitative and quantitative evidence from primary interviews with industry leaders, technical validation exercises, and secondary literature across peer-reviewed journals, regulatory guidance, and publicly disclosed product filings. Source triangulation ensured that claims reflect convergent evidence from practitioner experience, technical benchmarks, and regulatory trends. The analytical framework combined a technology stack view, data lifecycle analysis, and go-to-market mapping to evaluate opportunities and risks across deployment, component, data type, end user, technology, and application dimensions.

Validation activities included scenario testing of deployment architectures, sensitivity analysis of procurement pathways in the face of tariff changes, and cross-site model reproducibility checks using representative clinical and imaging datasets. Quality controls encompassed standardized interview protocols, independent code reviews of analytic scripts, and peer review of the narrative by subject matter experts in regulatory affairs, clinical operations, and data governance. Ethical considerations focused on data privacy, bias mitigation, and the implications of model error in clinical contexts.

Limitations are acknowledged where proprietary data or emerging regulatory decisions constrain definitive conclusions. Where appropriate, the research highlights assumptions underlying scenario analyses and identifies areas where additional primary data collection would strengthen confidence. The methodology is designed to be transparent and reproducible, enabling clients to request deeper dives or methodological appendices aligned to their specific evidence needs.

Concluding synthesis that distills strategic imperatives, risk mitigations, and next-step considerations for health system leaders, biopharma executives, and research institutions

Synthesis of the evidence points to several enduring imperatives: align AI investments with clearly articulated clinical or research outcomes, invest in governance and reproducibility to navigate regulatory expectations, and adopt flexible architectures that balance innovation speed with data sovereignty and operational stability. Organizations that follow these principles will be better positioned to convert technical advances into measurable improvements in discovery pipelines, clinical workflows, and patient outcomes.

Risk mitigation requires active management of supply chain exposures, especially in light of evolving trade policies that affect hardware and integrated systems. Similarly, talent scarcity and organizational friction can be overcome by deliberate reskilling programs and by embedding data operations into core business processes. Strategic partnerships remain a durable mechanism to access specialized expertise, accelerate validation, and scale solutions across institutions and geographies.

Looking forward, the interplay between model sophistication, data stewardship, and regulatory adaptation will determine how quickly AI moves from promising pilots to standard practice. Institutions that embrace cross-functional collaboration, robust measurement, and pragmatic technology choices will capture the greatest value while maintaining safety and public trust.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Life Sciences Market, by Component

  • 8.1. Hardware
    • 8.1.1. Processors & Accelerators
    • 8.1.2. Servers & Workstations
    • 8.1.3. Storage & Networking
  • 8.2. Services
    • 8.2.1. Consulting
    • 8.2.2. Integration
    • 8.2.3. Support & Maintenance
  • 8.3. Software
    • 8.3.1. Platforms
    • 8.3.2. Solutions
    • 8.3.3. Tools & Frameworks

9. Artificial Intelligence in Life Sciences Market, by Data Type

  • 9.1. Clinical Data
    • 9.1.1. Electronic Health Records
    • 9.1.2. Lab Results
  • 9.2. Genomic Data
    • 9.2.1. Gene Expression Data
    • 9.2.2. Sequencing Data
  • 9.3. Imaging Data
    • 9.3.1. CT Scans
    • 9.3.2. MRI
    • 9.3.3. Ultrasound
    • 9.3.4. X Ray

10. Artificial Intelligence in Life Sciences Market, by Deployment

  • 10.1. Cloud
    • 10.1.1. Hybrid Cloud
    • 10.1.2. Private Cloud
    • 10.1.3. Public Cloud
  • 10.2. On Premise

11. Artificial Intelligence in Life Sciences Market, by Technology

  • 11.1. Computer Vision
    • 11.1.1. 3D Reconstruction
    • 11.1.2. Medical Imaging Analysis
    • 11.1.3. Pattern Recognition
  • 11.2. Machine Learning
    • 11.2.1. Deep Learning
    • 11.2.2. Reinforcement Learning
    • 11.2.3. Supervised Learning
    • 11.2.4. Unsupervised Learning
  • 11.3. Natural Language Processing
    • 11.3.1. Semantic Analysis
    • 11.3.2. Speech Recognition
    • 11.3.3. Text Mining
  • 11.4. Predictive Analytics
    • 11.4.1. Outcome Prediction
    • 11.4.2. Risk Modeling
  • 11.5. Robotic Process Automation

12. Artificial Intelligence in Life Sciences Market, by End User

  • 12.1. Contract Research Organizations
  • 12.2. Healthcare Providers
    • 12.2.1. Clinics
    • 12.2.2. Diagnostic Centers
    • 12.2.3. Hospitals
  • 12.3. Pharmaceutical & Biotechnology Companies
  • 12.4. Research Organizations

13. Artificial Intelligence in Life Sciences Market, by Application

  • 13.1. Clinical Trial Management
    • 13.1.1. Data Management
    • 13.1.2. Patient Recruitment
    • 13.1.3. Trial Design
  • 13.2. Diagnostics & Imaging
    • 13.2.1. Genomic Imaging
    • 13.2.2. Pathology Imaging
    • 13.2.3. Radiology Imaging
  • 13.3. Drug Discovery
    • 13.3.1. Lead Optimization
    • 13.3.2. Target Identification
    • 13.3.3. Toxicology Prediction
  • 13.4. Patient Monitoring
    • 13.4.1. Remote Monitoring
    • 13.4.2. Wearable Devices
  • 13.5. Treatment Personalization
    • 13.5.1. Dose Optimization
    • 13.5.2. Precision Medicine

14. Artificial Intelligence in Life Sciences Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Artificial Intelligence in Life Sciences Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Artificial Intelligence in Life Sciences Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Artificial Intelligence in Life Sciences Market

18. China Artificial Intelligence in Life Sciences Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Atomwise
  • 19.6. BenevolentAI
  • 19.7. BioAge Labs
  • 19.8. Cyclica
  • 19.9. Exscientia
  • 19.10. GNS Healthcare
  • 19.11. Google Health
  • 19.12. Healx
  • 19.13. IBM Watson Health
  • 19.14. Iktos
  • 19.15. Insilico Medicine
  • 19.16. Microsoft Corporation
  • 19.17. NVIDIA Corporation
  • 19.18. PathAI
  • 19.19. Recursion Pharmaceuticals
  • 19.20. ReviveMed
  • 19.21. Schrodinger, Inc.
  • 19.22. SOPHiA GENETICS
  • 19.23. Standigm
  • 19.24. Tempus Labs
  • 19.25. Valo Health
  • 19.26. Verily Life Sciences
  • 19.27. XtalPi
  • 19.28. Zephyr AI

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEPLOYMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PROCESSORS & ACCELERATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PROCESSORS & ACCELERATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PROCESSORS & ACCELERATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVERS & WORKSTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVERS & WORKSTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVERS & WORKSTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY STORAGE & NETWORKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY STORAGE & NETWORKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY STORAGE & NETWORKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY INTEGRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY INTEGRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY INTEGRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOOLS & FRAMEWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOOLS & FRAMEWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOOLS & FRAMEWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ELECTRONIC HEALTH RECORDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ELECTRONIC HEALTH RECORDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ELECTRONIC HEALTH RECORDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LAB RESULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LAB RESULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LAB RESULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENE EXPRESSION DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENE EXPRESSION DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENE EXPRESSION DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEQUENCING DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEQUENCING DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEQUENCING DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CT SCANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CT SCANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CT SCANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY 3D RECONSTRUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY 3D RECONSTRUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY 3D RECONSTRUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MEDICAL IMAGING ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MEDICAL IMAGING ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MEDICAL IMAGING ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATTERN RECOGNITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATTERN RECOGNITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATTERN RECOGNITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REINFORCEMENT LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REINFORCEMENT LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY UNSUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY UNSUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEMANTIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEMANTIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEMANTIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SPEECH RECOGNITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SPEECH RECOGNITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SPEECH RECOGNITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TEXT MINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TEXT MINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TEXT MINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY OUTCOME PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY OUTCOME PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY OUTCOME PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RISK MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RISK MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RISK MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT RECRUITMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT RECRUITMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT RECRUITMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TRIAL DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TRIAL DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TRIAL DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATHOLOGY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATHOLOGY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATHOLOGY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RADIOLOGY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RADIOLOGY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RADIOLOGY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOXICOLOGY PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOXICOLOGY PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOXICOLOGY PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REMOTE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REMOTE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REMOTE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DOSE OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DOSE OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DOSE OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRECISION MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRECISION MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRECISION MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 249. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 250. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 251. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 252. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA ARTIFICIAL I